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Glutamate and GABA are the quantitatively major neurotransmitters in the brain mediat-
ing excitatory and inhibitory signaling, respectively. These amino acids are metabolically
interrelated and at the same time they are tightly coupled to the intermediary metabolism
including energy homeostasis. Astrocytes play a pivotal role in the maintenance of the
neurotransmitter pools of glutamate and GABA since only these cells express pyruvate
carboxylase, the enzyme required for de novo synthesis of the two amino acids. Such de
novo synthesis is obligatory to compensate for catabolism of glutamate and GABA related
to oxidative metabolism when the amino acids are used as energy substrates. This, in
turn, is influenced by the extent to which the cycling of the amino acids between neurons
and astrocytes may occur. This cycling is brought about by the glutamate/GABA – gluta-
mine cycle the operation of which involves the enzymes glutamine synthetase (GS) and
phosphate-activated glutaminase together with the plasma membrane transporters for
glutamate, GABA, and glutamine.The distribution of these proteins between neurons and
astrocytes determines the efficacy of the cycle and it is of particular importance that GS
is exclusively expressed in astrocytes. It should be kept in mind that the operation of the
cycle is associated with movement of ammonia nitrogen between the two cell types and
different mechanisms which can mediate this have been proposed.This review is intended
to delineate the above mentioned processes and to discuss quantitatively their relative
importance in the homeostatic mechanisms responsible for the maintenance of optimal
conditions for the respective neurotransmission processes to operate.
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INTRODUCTION
HISTORICAL PERSPECTIVE OF AMINO ACID NEUROTRANSMISSION:
GLUTAMATE AND GABA
The general concept in biochemistry that glutamate is a key
metabolite linking amino acid and glucose metabolism via the
tricarboxylic acid (TCA) cycle was extended when Eugene Roberts
discovered GABA in the brain. They showed that it was synthe-
sized from glutamate by decarboxylation of the C-1 carboxylic
group thereby adding an important functional property to glu-
tamate (1). Further studies of glutamate and GABA metabolism
led to the biochemical term “the GABA shunt” (2) which inter-
connects the TCA cycle with glutamate and GABA metabolism
(Figure 1). While the basic biochemical metabolic pathways (see
below) involving glutamate and GABA metabolism were worked
out from 1950 and onward it was not until the end of this decade
that pioneering electrophysiological studies of spinal cord neurons
led to the understanding that glutamate and GABA act as excita-
tory and inhibitory substances (3, 4). Due to the fact that these
amino acids were present in much higher concentrations than the
classical neurotransmitters acetylcholine and the monoamines it
took several years until it was generally accepted that these two
amino acids are not just metabolites but they constitute the quan-
titatively most important neurotransmitters in the central nervous
system [see reviews by Ref. (5) and (6)].
CONTENT
BIOSYNTHETIC PATHWAYS FOR TRANSMITTER GLUTAMATE AND
GABA
Glutamate
It is commonly accepted that the enzyme catalyzing the hydrol-
ysis of glutamine to glutamate, glutaminase is the functionally
most important enzyme for the biosynthesis of glutamate [see
Ref. (7)] and since this enzyme is activated by phosphate it is rou-
tinely referred to as phosphate-activated glutaminase (PAG). This
enzyme was first described by Krebs (8) in an extensive study of
glutamine degradation and synthesis in different tissues includ-
ing the brain. The expression of PAG is higher in neurons than in
astrocytes (9, 10) but PAG is not specifically associated with glu-
tamatergic neurons as GABA synthesis in GABAergic neurons is
dependent upon glutamate derived from glutamine taken up from
surrounding astrocytes (see below).
There are actually alternative enzymatic reactions which are
able to produce glutamate from the TCA cycle intermediate α-
ketoglutarate. These are glutamate dehydrogenase (GDH) and
the aminotransferases. Among the latter aspartate aminotrans-
ferase (AAT), alanine-aminotransferase (ALAT), and the branched
chain aminotransferase (BCAAT) are the most likely candidates to
be involved in glutamate biosynthesis [for reactions and refer-
ences, see Ref. (11)]. While the aminotransferase reactions would
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FIGURE 1 | Schematic representation of theTCA cycle and the GABA
shunt which provides an alternative pathway for conversion of αKG to
succinate. (*) Please note that glutamate decarboxylase is localized in the
cytosol whereas all other enzymes depicted are mitochondrial. αKG,
α-ketoglutarate; SSADH, succinate-semialdehyde; GABA-T,
GABA-transaminase; GABA, γ-aminobutyrate; GAD, glutamate
decarboxylase; Glu, glutamate.
normally be in thermodynamic equilibrium the GDH reaction in
the brain is unlikely to be at thermodynamic equilibrium due
to low levels of ammonia and NADH/NADPH (12). The Km
for ammonia in the GDH-catalyzed reaction is in the millimo-
lar range, i.e., well above the level of ammonia found in the brain;
however, in a mitochondrial microenvironment close to the PAG
reaction in glutamatergic neurons, the level of ammonia might be
high enough for the reaction to proceed in the direction of reduc-
tive amination as initially suggested by Waagepetersen et al. (13)
and discussed by Bak et al. (14). In the liver, however, where the
substrate conditions are different the GDH reaction may well be
at thermodynamic equilibrium (15). As pointed out by Cooper
(12) the GDH-catalyzed reaction is often coupled to the amino-
transferases, which in the brain would result in ammonia being
produced from the amino group in the amino acids since the
GDH reaction would preferentially catalyze oxidative deamina-
tion of glutamate. This aspect will be discussed in more detail
below.
Based on experiments performed in cultured glutamatergic
cerebellar granule cells using phenylsuccinate to inhibit the ketodi-
carboxylate carrier in the mitochondrial membrane (16) a model
was proposed according to which (Figure 2) neurotransmitter
glutamate is generated by the concerted action of glutaminase
and the malate-aspartate-shuttle (MAS). According to this model
glutamate formed by the action of PAG located in the mito-
chondrial membrane (17) gets access to the mitochondrial matrix
where it is transaminated by AAT to form α-ketoglutarate which
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FIGURE 2 | Schematic drawing of the reactions involved in the
biosynthesis of neurotransmitter glutamate. Reactions involve the
elements of the malate-aspartate-shuttle (43), i.e., the glutamate/aspartate
translocator and the dicarboxylate transporter as indicated. Notice that a
significant fraction (about 50%) of glutamate derived from the reaction
catalyzed by phosphate-activated glutaminase (PAG) is directly entering
mitochondria presumably via the glutamate/aspartate translocater. It has
also been suggested that PAG is catalytically active in the mitochondrial
matrix (23, 24) although this is controversial [see text and Ref. (22)]. MDHc,
cytosolic malate dehydrogenase; MDHm, mitochondrial malate
dehydrogenase; AATc, cytosolic aspartate aminotransferase; AATm,
mitochondrial aspartate aminotransferase; OAA, oxaloacetate; Mal, malate;
Glu, glutamate; Asp, aspartate; GLN, glutamine; α-KG, α-ketoglutarate.
is translocated to the cytoplasm where it undergoes a second
transamination via AAT to produce glutamate. That this mech-
anism is indeed working is supported by the demonstration that
while oxidation of the carbon skeleton of glutamate in the TCA
cycle is dependent on activity of GDH (18), the formation of glu-
tamate from α-ketoglutarate is catalyzed by an aminotransferase
which is most likely mitochondrial AAT (19). This glutamate is
subsequently used for vesicular release (16). The translocation
processes require the operation of the aspartate-malate shuttle (see
Figure 2). In keeping with this the release of transmitter glutamate
could be inhibited not only by phenylsuccinate that inhibits the
dicarboxylate carrier (20) but also by aminooxyacetic acid that
inhibits AAT (20). It has been argued that glutamate generated
in the PAG catalyzed hydrolysis of glutamine is released from the
mitochondrial membrane into the cytosol and not into the matrix
[see Figure 2; (17, 21, 22)] but experiments using [13C]glutamine
and histamine to inhibit glutamine transport into the mitochon-
dria have provided evidence that glutamate generated in the PAG
catalyzed reaction does indeed get access to the mitochondrial
matrix (23, 24).
GABA
While no single enzyme can be used as a specific marker for glu-
tamatergic neurons (see above), the demonstration by Saito et al.
(25) using an antibody which specifically recognizes the GABA
synthesizing enzyme glutamate decarboxylase (GAD) that GAD
is associated selectively with GABAergic neurons has led to the
notion that GAD is a selective marker for GABAergic neurons.
The subsequent finding of GAD-like immunoreactivity in certain
glutamatergic neurons in the hippocampus (26, 27) may, however,
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indicate a more complex distribution of GAD the functional impli-
cations of which may not be easy to understand. It should be noted
in this context that GABA not only acts as transmitter but also
functions as a neurotrophic agent [see Ref. (28), and references
herein]. Cloning studies have revealed that isoenzymes of GAD
exist since two cytosolic forms of GAD with molecular weights of
65 and 67 kDa, respectively have been described [see Ref. (29) for
review]. The general notion is that the intracellular distribution
of the two isozymes is heterogeneous, since GAD65 is selectively
associated with GABAergic nerve endings and therefore plays an
important regulatory role in synthesis of neurotransmitter GABA
(30). This is compatible with the observation that GAD65 knock-
out (GAD65−/−) animals are susceptible to induced seizures (31,
32). GAD67 is found throughout the cytosol of these neurons and
therefore may serve as the biosynthetic enzyme for the GABA
pool associated with metabolism [i.e., consistent with a house-
keeping function; see Ref. (33)]. It may be noted that GAD67
knock-outs (GAD67−/−) are lethal while heterozygotes are viable
and have no seizure sensitivity contrary to the GAD65 knock-outs
(31, 34).
As illustrated in Figure 3 the biosynthesis of neurotransmitter
GABA may be somewhat more complex than originally thought of
as studies of GABA synthesis from [13C]glutamine have revealed
that the synthesis involves mitochondrial TCA cycle metabolism
(35, 36). As pointed out above hydrolysis of glutamine by PAG
leads to generation of glutamate in the mitochondrial matrix and
this glutamate needs to be transaminated to form α-ketoglutarate
in order for the carbon skeleton to leave the mitochondria (see
Figure 2). Since GAD is a cytosolic enzyme (37) the decarboxyla-
tion of glutamate to form GABA can take place only in the cytosol.
As a result of the fact that at least some of the glutamate generated
in the PAG reaction may be released directly into the cytosol (17)
GABA can be formed either directly from glutamate in the cytosol
or from glutamate originating from α-ketoglutarate produced in
the TCA cycle from oxidatively deaminated glutamate involving
GDH. These two pathways seem to be almost equally important
for biosynthesis of transmitter GABA (35, 36). The functional sig-
nificance of the mitochondrial involvement in GABA biosynthesis
PAG
AAT
AAT
GAD
GADCytosol
Mitochondria
FIGURE 3 | An illustration of two pathways for GABA synthesis from
glutamine. The bold arrow illustrates the predominant pathway where the
carbon skeleton of glutamine is metabolized via the TCA cycle prior to
synthesis of GABA. The thin arrow illustrates the direct synthesis of GABA
from glutamine without involvement of the TCA cycle. Note that AAT is
present in both the cytosol and the mitochondrial matrix. αKG,
α-ketoglutarate; PAG, phosphate-activated glutaminase; ATT, aspartate
aminotransferase; GAD, glutamate decarboxylase.
is not well understood but it may provide additional possibilities
for regulatory mechanisms to operate.
METABOLIC PATHWAYS FOR DEGRADATION OF GLUTAMATE AND
GABA
While the primary event responsible for inactivation of the neu-
rotransmitter action of glutamate and GABA is related to the
high-affinity transporters for these amino acids, the subsequent
intracellular metabolic pathways for degradation of glutamate
and GABA are of functional significance [Ref. (38) and references
herein]. A discussion of the transporters will follow below.
The enzymes of interest are glutamine synthetase (GS), GDH,
and aminotransferases (or transaminases) in relation to glutamate.
In case of GABA the pertinent enzymes are GABA-transaminase
(GABA-T) and succinic semialdehyde dehydrogenase (SSADH).
GS is a cytosolic enzyme while GDH, SSADH, and GABA-T are
located in the mitochondria [Ref. (34) and references herein].
Except for GS which is strictly astroglial (39) these enzymes are
expressed both in neurons and astrocytes. Transgenic or knock
out animals of these enzymes (GS, GDH, and SSADH) have
provided evidence that they are of significant, functional impor-
tance for the maintenance of homeostatic mechanisms related
to the cellular contents as well as to the neurotransmitter func-
tion. Thus, GDH knock outs exhibit impaired astrocytic glutamate
oxidation and increased glutamine synthesis pointing to a more
prominent cycling of glutamate which may be compatible with
the observation that synaptic glutamatergic function remained
intact (40). On the other hand, GS homozygote knock outs are
lethal and heterozygotes exhibit increased susceptibility to seizures
(41). SSADH−/− animals exhibit altered neurotransmitter GABA
metabolism and increased seizure activity which may result in
lethal status epilepticus [see Ref. (34)].
ROLE OF ASTROCYTES PROVIDING GLUTAMINE, THE PRECURSOR FOR
GLUTAMATE AND GABA
Glutamine serves a very important role in glutamatergic and
GABAergic neurotransmission, as it constitutes the only precur-
sor for the biosynthesis of these two amino acid neurotransmitters
(see above). Due to the fact that GS as stated above is exclusively
expressed in astrocytes these cells play a unique role in supply-
ing the precursor for the transmitter in both glutamatergic and
GABAergic neurons [see Ref. (38) and references therein]. This
requires a symbiotic relationship between the neuronal and astro-
cytic compartments since an exchange of glutamine and the trans-
mitter amino acids is necessary. This is illustrated in Figure 4 which
is a schematic representation of the glutamate/GABA-glutamine
cycle operating between the nerve endings of glutamatergic or
GABAergic neurons and surrounding astrocytes. This cycle was
originally thought to operate in a stoichiometric fashion maintain-
ing the carbon skeleton of the transmitter amino acids intact (42).
However, the demonstration of a significant oxidative metabolism
of both glutamate and GABA via the TCA cycle [see Ref. (43)]
makes it impossible for this cycle to operate in a stoichiometric
way as at least part of the glutamate and GABA skeleton will be
lost as carbon dioxide. It is therefore imperative that such a loss is
compensated for byde novo synthesis of the carbon skeleton of glu-
tamate and subsequently glutamine. As ultimately the precursor
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FIGURE 4 | Schematic cartoon depicting the metabolic interactions
between a glutamatergic neuron, a GABAergic neuron, and a nearby
astrocyte. In all three cell types, glucose (Glc) is metabolized to pyruvate via
the multi-step process of glycolysis and either reduced to lactate (by lactate
dehydrogenase, LDH) or oxidized to acetyl-CoA (by pyruvate dehydrogenase
complex, PDH) which will subsequently be oxidized in the TCA cycle. In
astrocytes, pyruvate may also undergo carboxylation to form oxaloacetate
(OAA), an anaplerotic reaction catalyzed by pyruvate carboxylase (PC). At the
glutamatergic synapse, glutamate (GLU) released as neurotransmitter will
be taken up by nearby astrocytes and amidated to glutamine (GLN) by
glutamine synthetase (GS) and returned to the neuron for re-use as
neurotransmitter, the so-called glutamate-glutamine cycle. In neurons, GLU
is re-formed from GLN by the mitochondrial enzyme phosphate-activated
glutaminase (PAG). A similar cycle exists at the GABAergic synapse;
however, the carbon skeleton of GABA enters the TCA cycle as indicated.
GABA is transformed to the TCA cycle intermediate succinate via two
reactions catalyzed by GABA-transaminase (GABA-T) and succinic
semialdehyde dehydrogenase (SSADH). The GABA-T catalyzed reaction
produces GLU from α-KG that may then be used as precursor for GLN
synthesis and eventual synthesis of GABA in the neuron. This process is
known as the GABA shunt since it by-passes two reactions of the
(astrocytic) TCA cycle. In GABAergic neurons, GABA is synthesized from
GLU by the enzyme glutamate decarboxylase (GAD). Notice that in all three
cell types, GLU is in transamination equilibrium (catalyzed by
aminotransferases, AT) with α-KG linking TCA cycle metabolism with GLU
and GABA homeostasis. Also notice that re-uptake of released GLU and
GABA takes place to some extent as well and that the GABA shunt works in
GABAergic neurons when GABA is taken up pre-synaptically.
must originate from the TCA cycle in the form of an intermedi-
ary which most likely is α-ketoglutarate (Figure 5) an anaplerotic
mechanism must be operating involving de novo synthesis of
oxaloacetate. In the brain this is most likely catalyzed by pyru-
vate carboxylase (PC) which has a higher activity than the other
enzymes capable of synthesizing oxaloacetate, i.e., malic enzyme
(ME) and phosphoenolpyruvate carboxykinase (44). Interestingly,
PC is like GS an astrocytic enzyme (45, 46) and accordingly de novo
synthesis of the carbon skeleton of glutamate and GABA via glu-
tamine requires astrocytic participation [see Ref. (43, 47)]. It has
been estimated that this anaplerotic,denovo synthesis of glutamine
may account for replenishment of approximately 25–30% of the
glutamate transmitter pool [see Ref. (43)]. It would be assumed,
that this would be associated with a comparable complete oxida-
tion of glutamate to carbon dioxide, a process requiring pyruvate
recycling (Figure 6). It may therefore seem somewhat enigmatic
that the activity of pyruvate recycling in the brain as well as in
cultured brain cells appears relatively modest (43).
CELLULAR DISTRIBUTION OF GLUTAMINE TRANSPORTERS
As a consequence of the astrocytic localization of de novo synthesis
of glutamine, a mechanism must exist which can mediate trans-
port of glutamine out of the astrocytes and into glutamatergic
and GABAergic neurons, respectively. This mechanism consists of
a unique set of glutamine membrane transporters located either
on astrocytes or the two sets of neurons. These transporters are
referred to as System A transporters in neurons and System N
transporters in astrocytes (14, 48). The System A family includes
SNAT1, 2, and 4 and System N consists of SNAT3 and 5 (14).
Each of these cloned transporters have alternative names making
the nomenclature confusing [for a comprehensive review, see Ref.
38)]. These transporters are regulated in complex ways with regard
to expression and kinetics underlining the functional importance
of the transporters (38).
ROLE OF GLUTAMATE TRANSPORTERS IN MAINTENANCE OF THE
GLUTAMATE NEUROTRANSMITTER POOL, I.E., UPTAKE OF GLUTAMATE
IN GLUTAMATERGIC NEURONS VERSUS ASTROCYTES
Detailed studies of the cellular localization of the most abun-
dantly expressed glutamate transporters, GLAST (EAAT-1) and
Glt-1 (EAAT-2) have provided compelling evidence that these glu-
tamate transporters are expressed predominately in astrocytes (5,
49, 50). In addition to these astrocytic glutamate transporters, a
neuronal counterpart (EAAC-1 or EAAT-3) has been cloned (51)
and it has been proposed that if located in the plasma membrane
of neurons, this transporter could participate in the maintenance
of the pool of transmitter glutamate and GABA (52–54). However,
a recent detailed study of the expression of EAAC-1 relative to that
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FIGURE 5 |The astrocytic part of the synapse provides a net synthesis of
glutamine (GLN) via the concerted action of pyruvate carboxylase (PC)
and pyruvate dehydrogenase (PDH) generating OAA and acetyl-CoA, the
combination of which leads to synthesis of CIT. This subsequently leads to
a net synthesis of α-ketoglutarate (α-KG) allowing synthesis of glutamate
(GLU) catalyzed by either glutamate dehydrogenase (GDH) or an amino acid
aminotransferase (AA). Glutamate is used for synthesis of glutamine (GLN)
catalyzed by glutamine synthetase (GS). Glutamine is transferred to the
glutamatergic neuron to be used for synthesis of glutamate catalyzed by
phosphate-activated glutaminase (PAG). Released glutamate is taken up into
the astrocyte and transformed into glutamine completing the
glutamate-glutamine cycle. Alternatively the glutamate taken up may be
oxidatively metabolized which subsequently requires de novo synthesis of
glutamine via the anaplerotic processes indicated in bold arrows.
of GLT-1 and GLAST has shown that the expression level of the
neuronal glutamate transporter EAAC-1 is very low and hence,
it is enigmatic how this transporter can contribute significantly
to removal of transmitter glutamate released from glutamatergic
neurons thereby via re-uptake into the presynaptic nerve endings
replenishing the transmitter pool of glutamate (55). Nevertheless,
a functional study in glutamatergic neurons has shown that even
in the presence of glutamine in the incubation medium, block
of glutamate transport using the specific glutamate transporter
inhibitor threo-benzyloxy-aspartate (TBOA) caused a significant
decrease in the cellular glutamate content after repetitive release of
glutamate from the transmitter pool (56). Additionally, it has been
shown that the non-metabolizable glutamate analog d-aspartate
is taken up into presynaptic nerve endings (57) as well as into
cultured glutamatergic neurons with only a marginal astrocytic
contamination (58). Altogether, these studies point to a quantita-
tively more important role of astrocytic glutamate uptake relative
to that associated with neurons in the inactivation of transmitter
glutamate. This notion is in keeping with the functional role of
the glutamate-glutamine cycle and it fits with the model proposed
by Hertz and Schousboe (59) based on analysis of kinetic data for
glutamate uptake into cultured neurons and astrocytes.
ROLE OF GABA TRANSPORTERS FOR MAINTENANCE OF GABA
NEUROTRANSMISSION
The concept of termination of GABA mediated neurotransmis-
sion via high-affinity transport is based on pioneering studies by
Elliott and Van Gelder (60) demonstrating that GABA was accu-
mulated by cerebral cortical slices from the incubation medium
against a concentration gradient. The high-affinity nature of the
transport mechanism was demonstrated by Iversen and Neal (61)
also using brain slices and this study showed GABA uptake in
both neurons and astrocytes. Detailed kinetic studies of GABA
uptake in cultured neurons and astrocytes [for review, see Ref.
(62, 63)] have shown that the neuronal GABA uptake is more
efficacious than that in astrocytes as schematically illustrated
by Hertz and Schousboe (59). Hence, only 10–20% of synapti-
cally released GABA will be taken up into astrocytic processes
whereas the remaining GABA is re-accumulated in the presy-
naptic nerve endings of the GABAergic neurons where it may
be re-utilized as a neurotransmitter after packaging in vesicles
(64). This is in contrast to the scenario described above for
glutamatergic neurotransmission in which the majority of the
released transmitter is taken up into astrocytes which ensheathe
the synapse.
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FIGURE 6 |The extent to which glutamate (GLU) is oxidized in
astrocytes seems to increase particularly during higher glutamate
concentrations. A net synthesis of tricarboxylic acid (TCA) cycle
intermediates occurs when the initial reaction is catalyzed by glutamate
dehydrogenase (GDH) which paves the way for the complete oxidation of
the carbon skeleton of glutamate. This requires pyruvate recycling via the
concerted action of malic enzyme (ME) and pyruvate dehydrogenase (PDH)
converting malate into acetyl CoA producing NAD(P)H. Acetyl CoA is
oxidized completely in one turn of the TCA cycle. A partial oxidation of
glutamate is acquired when pyruvate (PYR) is reduced to lactate (LAC)
instead of being oxidized to acetyl CoA. The redox state of the cell is likely
important in the regulation of the destiny of the glutamate molecule. As an
alternative to the activity of GDH, aspartate aminotransferase (AAT)
facilitates the formation of α-ketoglutarate (α-KG) from glutamate at the
expense of oxaloacetate (OAA); thus no net synthesis of TCA cycle
intermediates is obtained. In contrast to the complete oxidation initiated by
the activity of GDH, AAT enables the truncated TCA cycle which refers to
the net synthesis of aspartate from glutamate, a pathway shown to
accelerate during hypoglycemic conditions. All enzymes except ME and
LDH are located in the mitochondria. PC, pyruvate carboxylase; CIT, citrate.
The high-affinity GABA transporters have been cloned and four
distinct transport proteins have been described three of which are
specific for GABA and one is able to transport both GABA and
the osmolyte betaine [for references, see Ref. (38)]. The nomen-
clature of these transporters is unfortunately somewhat confusing
but it is recommended to utilize the HUGO nomenclature, i.e.,
GAT1, GAT2, and GAT3 for the GABA specific transporters and
BGT1 for the betaine-GABA transporter (38, 65, 66). Among these
transporters, GAT1 is the most prevalent being expressed both in
GABAergic neurons and in astrocytes. GAT2 is expressed neona-
tally in the brain but its expression decreases as a function of post-
natal development. GAT3 may be considered primarily astrocytic
while BGT1 is only sparsely expressed in the brain [for references,
see Ref. (38)]. While pharmacological studies have pointed to an
interesting function of BGT1 and possibly GAT3 for the control
of the availability of GABA at extrasynaptic GABA receptors (67)
the low expression level of BGT1 has questioned the quantitative
significance of this transporter for GABA homeostasis (68).
The fact that aberrations in GABA neurotransmission are asso-
ciated with a number of neurological diseases including epilepsy
[see Ref. (34) for references] has prompted detailed pharmacolog-
ical studies of GABA transporters to be performed [for references,
see Ref. (66)]. This has resulted in development of the clinically
active antiepileptic drug tiagabine which is a specific inhibitor of
GAT1 (34) and more recently such studies have been focusing
on development of inhibitors acting preferentially on non-GAT1
transporters (69). This has led to synthesis of a GABA analog
which preferentially inhibits BGT1 and which exhibits anticon-
vulsant activity (70). This is an indication that astrocytic GABA
transport may represent an interesting pharmacological target as
proposed previously (71, 72).
AMMONIA HOMEOSTASIS RELATED TO THE GLUTAMATE-GLUTAMINE
CYCLE AND SHUTTLING OF NITROGEN BETWEEN NEURONS AND
ASTROCYTES
As seen in Figure 4 the glutamate-glutamine cycle leads to pro-
duction of ammonia in glutamatergic neurons by the conversion
of glutamine to glutamate catalyzed by PAG. At the same time
ammonia is needed in the astrocytes for the synthesis of gluta-
mine from glutamate catalyzed by GS. This obviously requires a
mechanism by which the ammonium ion can be transported out of
the neurons and into the surrounding astrocytes. While ammonia
(NH3) may be able to diffuse through the plasma membrane it is
less likely that the charged ammonium (NH+4 ) ion can penetrate
the lipid double layer of these membranes and at physiological
pH essentially all ammonia is in the ionized form of ammonium.
It has therefore been proposed that an amino acid based shuttle
mechanism may be operating between the neuronal and the astro-
cytic compartments [see Ref. (14)]. The operation of one of the
models is based on the use of alanine as the nitrogen-carrier (13,
73) while the other analogous model has proposed that branched
chain amino acids (BCAAs) and their congeneric keto-acids play
this role (74). Regardless of the model there is a requirement for
a reductive amination of α-ketoglutarate to glutamate catalyzed
by GDH to take place with a simultaneous transamination of this
glutamate to either alanine of a BCAA to occur [see Ref. (11)
for details]. As the thermodynamic equilibrium of the GDH-
catalyzed reaction and the high Km value for [NH
+
4 of GDH
counteract such amination (75)] it has been proposed that the
intra-mitochondrial milieu possibly coupled to a metabolomic
complex between PAG, GDH, and the transaminases in question,
i.e., ALAT and BCAA-aminotransferase may facilitate the reac-
tions (11). Actually, a metabolomic coupling between GDH and
ALAT as well as BCAA-aminotransferase has been experimentally
demonstrated (76, 77).
A recent review paper by Rothman et al. (78) has provided
a careful analysis of the functional capability of the above men-
tioned shuttles to support the flux of nitrogen from neurons to
astrocytes needed to balance the rate of de novo synthesis of gluta-
mine to compensate for oxidative metabolism of glutamate in the
astrocytic compartment. While the rate of ammonia fixation by the
GDH reaction and the activity of the transaminases involved in the
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proposed shuttles may be sufficient to match the rate of glutamine
synthesis, the modeling studies show that the actual fluxes of either
the alanine/lactate or the BCAA/branched chain keto-acid shut-
tles are insufficient to account for the need of ammonia nitrogen
to account for glutamine synthesis. Hence, the exact mechanisms
involved in ammonia nitrogen transfer between the neuronal and
astrocytic compartments remain to be fully elucidated.
ENERGY SUBSTRATES FOR THE OPERATION OF GLUTAMATE/GABA
CYCLING. GLYCOGEN, GLUCOSE, LACTATE, OR GLUTAMATE
Energy cost related to cycling
Since the transporters for glutamate and GABA are dependent on
an intact trans-membrane sodium ion gradient maintained by the
operation of the Na+-K+-ATPase it is clear that transport of the
amino acids is strongly dependent on chemical energy supplied
by ATP hydrolysis [see Ref. (43)]. Additionally, in case glutamate
transported into astrocytes is metabolized to glutamine one mol-
ecule of ATP is used per glutamate in the GS catalyzed reaction.
As will be discussed below, glutamate may alternatively function
as an energy producing molecule in case it is oxidatively metabo-
lized via the GDH-catalyzed reaction and subsequent metabolism
of the carbon skeleton to CO2 in the TCA cycle. However, since
glucose is the most important energy fuel for the brain under nor-
mal physiological conditions (43), the following sections shall deal
with glucose and its associated molecules glycogen and lactate as
energy sources. Glutamate as an energy source will be discussed
separately.
Glycogen as energy source
The brain has a small but apparently functionally significant store
of glycogen which is selectively located in the astrocytes [Ref. (79)
and references herein]. It can be used during an energy crisis, i.e.,
reduced blood supply and/or aglycemia but recent studies have
provided evidence that glycogen is a highly dynamic molecule
which via the glycogen-shunt (Figure 7) channels a significant
part of the glucose carbon entering the brain into glycolysis
(79, 80). Studies utilizing drugs selectively inhibiting glycogen
phosphorylase, the key enzyme in glycogenolysis have convinc-
ingly demonstrated that a continuous functional activity of the
glycogen-shunt is a prerequisite for the maintenance of optimal
glutamatergic activity and for functional and behavioral activi-
ties associated with such neurotransmission including memory
formation and consolidation [for references, see Ref. (79) and
(81)]. This obviously places the astrocytes in a key functional
role since as mentioned above glycogen is exclusively found in
astrocytes.
Glucose versus lactate as energy source
Whether or not glucose is metabolized through the glycogen-
shunt its carbon skeleton enters the glycolytic metabolic pathway
as glucose-6-phosphate and through a series of reactions referred
to as the glycolytic pathway, the glucose molecule consisting of six
carbon atoms is split into two molecules of pyruvate, i.e., two C-3
units (43). This results in a net production of two molecules of
ATP if the glycogen-shunt is not operating since the hexokinase
step consumes an ATP while three molecules of ATP are gained
when the glycogen-shunt is in operation since the hexokinase
GLUCOSE-6-P
LACTATEPYRUVATE
GLYCOGEN 
Glycogen phosphorylase
Glycogen synthase
GLUCOSE GLUCOSE
AT
P TCA
cycle
+
ETC
AT
P
LACTATE
Astrocyte
FIGURE 7 | A simplified schematic representation of glucose
metabolism via glycolysis or via the “glycogen-shunt” illustrating how
glucose units may be metabolized via incorporation into and
subsequent hydrolysis from the branched glycogen molecule
preceding metabolism to pyruvate and lactate, i.e., glycogenolysis.
Glucose-6-P, glucose-6-phosphate; TCA, tricarboxylic acid; ETC, electron
transport chain.
step is circumvented. Therefore from a purely energetic efficiency
point of view there is a dramatic advantage of the operation of the
glycogen-shunt increasing the energy production of the glycolytic
pathway by 50%. The two moles of pyruvate formed in glycoly-
sis from glucose can either be converted to two moles of lactate
or they can be oxidized to CO2 in the pyruvate dehydrogenase
(PDH)/TCA cycle reactions. In the latter case the NADH+H+
produced in the oxidative processes of the glycolytic pathway are
available for oxidative phosphorylation in the mitochondrial res-
piratory chain while in the former case the reduced co-enzyme is
oxidized in the lactate dehydrogenase (LDH) catalyzed conversion
of pyruvate to lactate [see Ref. (43) for further details]. It must
be emphasized that in case pyruvate is to enter the PDH/TCA
cycle pathway a mechanism capable of transferring reduced co-
enzyme equivalents from the cytoplasm to the mitochondria and
vice versa must exist or else the cytoplasmic content of NAD+
will be depleted. The shuttling mechanism for transfer of reduced
co-enzyme equivalents across the mitochondrial membrane is of
fundamental importance and the most important mechanism for
this in the brain is the MAS discussed above in relation to the
biosynthetic pathway for transmitter glutamate (43). While there
is consensus about the presence of the MAS in neurons its expres-
sion level in astrocytes has been questioned (82). It should be
noted, however, that a transcriptomic analysis of acutely isolated
astrocytes has provided evidence that this shuttle is present in
astrocytes (9, 83) which is in keeping with the high expression
of all enzymes necessary for oxidation of glucose and the actual
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functional activity of complete glucose oxidation in these cells
(9, 84).
The hypothesis proposed by Pellerin and Magistretti (85) that
glutamate recycling in the glutamate-glutamine cycle is tightly
coupled to astrocytic glycolysis converting glucose essentially
quantitatively to lactate and that this lactate is transferred to neu-
rons for complete oxidation [the astrocyte-neuron-lactate-shuttle
(ANLS) has been a subject of considerable debate (84, 86, 87)].
The fact that astrocytes have a considerable oxidative metabolism
of glucose (84) and that lactate can be transferred bi-directionally
between neurons and astrocytes (88–91) is not in favor of ANLS
being the unifying hypothesis of glucose metabolism and trans-
fer of lactate to neurons to serve as the major energy substrate in
these cells. Actually, it has been shown that glucose and not lactate
is required to maintain glutamatergic activity in cultured cerebel-
lar granule cells, a glutamatergic neuronal preparation (92–94).
Additionally, Zielke et al. (95) have elegantly demonstrated that
at least half of the extracellularly available glucose in the brain is
accumulated by neurons and that lactate is metabolized by both
neurons and astrocytes.
Glutamate as an energy substrate
The demonstration that glutamate can be oxidatively metabolized
to CO2 in cultured astrocytes (18, 96, 97) provides strong support
to the notion that the glutamate-glutamine cycle cannot oper-
ate in a stoichiometric fashion, i.e., that there is a 1:1 exchange
of glutamate and glutamine (Figure 4). It is, however, compati-
ble with a considerable pyruvate carboxylation enabling de novo
synthesis of glutamine to compensate for loss of glutamate by
oxidative metabolism (see above). That the carbon skeleton of
glutamate to a considerable extent gets access to the TCA cycle can
be deduced from experiments using [13C]glutamate and NMR
spectroscopy to study glutamate metabolism in cultured astro-
cytes. It could be demonstrated that glutamate-carbon labeled
lactate derived from the TCA cycle via ME activity more exten-
sively than glutamine formed in the GS catalyzed reaction (98).
It should be emphasized that complete oxidation of glutamate via
the combined action of the GDH reaction, pyruvate recycling and
the TCA cycle generates 75% of the energy in the form of ATP
that would be produced by oxidation of glucose. The significance
of glutamate as an energy source is further discussed by Kreft
et al. (81).
CONCLUDING REMARKS
A recent comprehensive review on astrocyte physiology and patho-
physiology (99) has provided compelling evidence to support the
view which has emerged over the past several years that these
cells constitute as aptly put by Hertz and Zielke (100): “The stars
of the show.” The present review has focused on the functional
role of astrocytes in relation to their regulatory function in amino
acid neurotransmission. The main conclusion is that these neuro-
transmission processes which operate in the vast majority of the
synapses in the brain would be completely dysfunctional with-
out astrocytic support and regulatory control. In this context it is
important to note that astrocyte morphology and process ramifi-
cation has undergone a dramatic increase in sophistication from
small rodents to humans which by far exceeds the corresponding
difference seen for nerve endings (101).
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